September 14, 2017

Favorable Interim Data Presented for Tyme’s SM-88 Phase 2 Trial for Prostate Cancer Patients

News

Tyme Technologies‘ SM-88 reduced the levels of circulating cancer cells — an indicator of metastatic disease — in all prostate cancer patients treated in an ongoing Phase 2 trial, according ... Read more

June 9, 2017

TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data

News

Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did not ... Read more